Aceso Life Science Group Limited (0474.HK)
HKD 0.04
(-4.88%)
HKD 0.04
(-4.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.36 Billion HKD | 9.83% |
| 2022 | 2.15 Billion HKD | -23.37% |
| 2021 | 2.81 Billion HKD | 9.92% |
| 2020 | 2.56 Billion HKD | 41.17% |
| 2019 | 1.81 Billion HKD | -16.54% |
| 2018 | 2.17 Billion HKD | 268.01% |
| 2017 | 590.67 Million HKD | 111.05% |
| 2016 | 279.87 Million HKD | -47.76% |
| 2015 | 535.73 Million HKD | 4.27% |
| 2014 | 513.77 Million HKD | 367.14% |
| 2013 | -192.32 Million HKD | -19.72% |
| 2012 | -160.64 Million HKD | -264.78% |
| 2011 | -44.04 Million HKD | -126.03% |
| 2010 | 169.15 Million HKD | 123.45% |
| 2009 | 75.7 Million HKD | 238.5% |
| 2008 | -54.65 Million HKD | 17.93% |
| 2007 | -66.6 Million HKD | -3.41% |
| 2006 | -64.4 Million HKD | -20.17% |
| 2005 | -53.59 Million HKD | 5.21% |
| 2004 | -56.54 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 2.36 Billion HKD | 649.68% |
| 2023 Q1 | 555 Million HKD | -74.27% |
| 2023 Q2 | 2.13 Billion HKD | 285.41% |
| 2023 Q3 | 316 Million HKD | -85.23% |
| 2023 FY | 2.36 Billion HKD | 9.83% |
| 2022 Q4 | 2.15 Billion HKD | 279.09% |
| 2022 Q3 | 569 Million HKD | -70.16% |
| 2022 FY | 2.15 Billion HKD | -23.37% |
| 2022 Q1 | 516 Million HKD | -81.67% |
| 2022 Q2 | 1.9 Billion HKD | 269.57% |
| 2021 Q2 | 2.2 Billion HKD | 3.52% |
| 2021 FY | 2.81 Billion HKD | 9.92% |
| 2021 Q1 | 2.12 Billion HKD | -16.87% |
| 2021 Q4 | 2.81 Billion HKD | 325.23% |
| 2021 Q3 | 662 Million HKD | -69.96% |
| 2020 Q3 | 1.74 Billion HKD | -8.0% |
| 2020 Q1 | 1.1 Billion HKD | -38.87% |
| 2020 FY | 2.56 Billion HKD | 41.17% |
| 2020 Q4 | 2.56 Billion HKD | 46.43% |
| 2020 Q2 | 1.9 Billion HKD | 71.42% |
| 2019 Q2 | 1.99 Billion HKD | 36.18% |
| 2019 FY | 1.81 Billion HKD | -16.54% |
| 2019 Q4 | 1.81 Billion HKD | 78.55% |
| 2019 Q3 | 1.01 Billion HKD | -48.98% |
| 2019 Q1 | 1.46 Billion HKD | -32.72% |
| 2018 Q1 | 1.01 Billion HKD | 72.51% |
| 2018 Q4 | 2.17 Billion HKD | 44.57% |
| 2018 Q3 | 1.5 Billion HKD | -16.33% |
| 2018 Q2 | 1.79 Billion HKD | 76.35% |
| 2018 FY | 2.17 Billion HKD | 268.01% |
| 2017 Q4 | 590.67 Million HKD | 335.6% |
| 2017 FY | 590.67 Million HKD | 111.05% |
| 2017 Q3 | -250.7 Million HKD | -301.96% |
| 2017 Q2 | 124.13 Million HKD | 173.84% |
| 2017 Q1 | -168.1 Million HKD | -160.07% |
| 2016 Q2 | 161.5 Million HKD | 149.16% |
| 2016 Q4 | 279.87 Million HKD | 149.75% |
| 2016 Q3 | -562.53 Million HKD | -448.31% |
| 2016 FY | 279.87 Million HKD | -47.76% |
| 2016 Q1 | -328.52 Million HKD | -161.32% |
| 2015 FY | 535.73 Million HKD | 4.27% |
| 2015 Q3 | -39.94 Million HKD | -116.43% |
| 2015 Q4 | 535.73 Million HKD | 1441.32% |
| 2015 Q2 | 243.11 Million HKD | 1014.95% |
| 2015 Q1 | -26.57 Million HKD | -105.17% |
| 2014 Q2 | 11.75 Million HKD | 107.32% |
| 2014 FY | 513.77 Million HKD | 367.14% |
| 2014 Q4 | 513.77 Million HKD | 970.44% |
| 2014 Q1 | -160.56 Million HKD | 16.51% |
| 2014 Q3 | -59.02 Million HKD | -602.34% |
| 2013 Q4 | -192.32 Million HKD | 52.2% |
| 2013 FY | -192.32 Million HKD | -19.72% |
| 2013 Q1 | -477.91 Million HKD | -197.49% |
| 2013 Q2 | -477.91 Million HKD | 0.0% |
| 2013 Q3 | -402.32 Million HKD | 15.82% |
| 2012 Q2 | -17.05 Million HKD | 89.63% |
| 2012 FY | -160.64 Million HKD | -264.78% |
| 2012 Q1 | -164.5 Million HKD | -127.69% |
| 2012 Q3 | -283.23 Million HKD | -1560.59% |
| 2012 Q4 | -160.64 Million HKD | 43.28% |
| 2011 Q2 | 445.59 Million HKD | 0.0% |
| 2011 Q4 | 594.01 Million HKD | 0.0% |
| 2011 FY | -44.04 Million HKD | -126.03% |
| 2010 Q4 | 169.15 Million HKD | 0.0% |
| 2010 Q2 | 196.9 Million HKD | 0.0% |
| 2010 FY | 169.15 Million HKD | 123.45% |
| 2009 FY | 75.7 Million HKD | 238.5% |
| 2009 Q4 | 75.7 Million HKD | 0.0% |
| 2008 FY | -54.65 Million HKD | 17.93% |
| 2007 FY | -66.6 Million HKD | -3.41% |
| 2006 FY | -64.4 Million HKD | -20.17% |
| 2005 FY | -53.59 Million HKD | 5.21% |
| 2004 FY | -56.54 Million HKD | 0.0% |